Veracyte services

Leverage the widely used Nanostring platform to study gene expression in the tumor microenvironment, revealing biomarker signatures, mechanism of action, disease biology, and more. The most popular Nanostring service we offer is the nCounter® PanCancer IO 360™ Panel. This panel is designed to deliver immuno-oncology insights for translational research and assesses the expression of 770 genes involved in the immune response to cancer in the tumor microenvironment. We offer additional Nanostring panels and custom panels designed to fit your specific needs.

From our proprietary biomarkers, our innovated assays solutions, our unique data analysis platforms and our CDx development capabilities, we offer a comprehensive family of biomarker services that enhance your insight into the tumor microenvironment (TME).

Veracyte has large capacity, high-throughput RNA-seq capabilities that speed turnaround-time for your studies. Our RNA-seq Services team can run your study using Illumina’s AmpliSeq and TruSight kits, or we can build a custom gene expression analysis panel to advance your project goals. As with all of our services, Veracyte provide detailed bioinformatic analysis and interpretation, to uncover insights from the data.

Veracyte’s professional framework for clinical trial assay (CTA) and companion diagnostics (CDx) development allows our clients to confidently advance priority projects. With an end-to-end service infrastructure, we support all aspects of assay development, manufacturing, life cycle management, regulatory submissions, marketing support, and commercialization for our partners.

Veracyte’s expertise in immuno-oncology and advanced data analytics delivers interpreted and actionable data using our proprietary platforms and technologies.